Comparison between a new platelet count drop method PL-11, light transmission aggregometry,VerifyNow aspirin system and thromboelastography for monitoring short-term aspirin effects in healthy individuals

Platelet function has been described by many laboratory assays, and PL-11 is a new point-of-care platelet function analyzer based on platelet count drop method, which counts platelet before and after the addition of agonists in the citrated whole blood samples. The present study sought to compare PL-11 with other three major more established assays, light transmission aggregometry (LTA), VerifyNow? aspirin system and thromboelastography (TEG), for monitoring the short-term aspirin responses in healthy individuals. Ten healthy young men took 100?mg/d aspirin for 3-day treatment. Platelet function was measured via PL-11, LTA, VerifyNow and TEG, respectively. The blood samples were collected at baseline, 2 hour, 1 day during the aspirin treatment and 1 day, 5?±?1 days, 8?±?1 days after the aspirin withdrawal. Moreover, 90 additional healthy subjects were recruited to establish a reference range for PL-11. Platelet function of healthy subjects decreased significantly 2 hours after 100?mg/d aspirin intake and began to recover during 4–6 days after the aspirin withdrawal. Correlations between methods were PL-11 vs. LTA (r?=?0.614, p?<?0.01); PL-11 vs. VerifyNow (r?=?0.829, p?<?0.01); PL-11 vs. TEG (r?=?0.697, p?<?0.001). There was no significant bias between PL-11 and LTA at baseline (bias?=?1.94%, p?=?0.804) using Bland-Altman analysis, while the data of PL-11 were significantly higher than LTA (bias?=?24.02%, p?<?0.001) during the aspirin therapy. The reference range for PL-11 in healthy young individuals was from 66.8 to 90.5% (95%CI). When aspirin low-responsiveness was defined as LTA?>?20%, the cut-off values for each method were, respectively: PL-11?>?50%, VerifyNow?>?533 ARU, TEG?>?60.2%. The results of different platelet function assays were uninterchangeable for monitoring aspirin response and correlations among them were also varied. Correlations among PL-11 and other three major assays suggested the ability of PL-11 to assess the treatment effects of aspirin. But a large cohort study is needed to confirm the cut-off value of aspirin response detected by PL-11.     

参麦注射液治疗心绞痛的临床观察

目的　探讨参麦注射液对冠心病 (CHD)心绞痛的治疗作用。方法　 80例患者分为两组 ,每组 4 0例 ,在常规治疗的基础上 ,对照组应用丹参注射液进行治疗 ,治疗组应用参麦注射液进行治疗。结果　治疗组有效 39例 (97.5 % ) ,心电图改善 38例 (95 .0 % ) ,对照组分别为 31例 (77.5 % )和 2 9例 (72 .5 % ) ,组间比较具有显著性差异 (P <0 .0 1)。结论　参麦注射液对冠心病心绞痛疗效显著 ,且安全、无明显副作用     

金珠滴眼液治疗慢性结膜炎的临床研究

目的　探讨金珠滴眼液治疗慢性结膜炎的疗效。方法　将慢性结膜炎患者 36例 6 8眼随机分为2组 ,每组 34眼 ,实验组用 7.8%金珠滴眼液点眼治疗 ,对照组用 0 .2 5 %氯霉素点眼治疗。结果　金珠滴眼液1、2、4周疗效的综合分值判定均与对照组有显著差异 (P <0 .0 5 ) ,且无局部刺激性。结论　金珠滴眼液对慢性结膜炎有明显的治疗作用 ,可望为临床常见多发的慢性结膜炎患者消除或缓解症状     

庆余肾气丸,复方丹参片中农药多残留分析

采用气相色谱法测定庆余肾气丸、复方丹参片中六六六，ＤＤＴ残留含量，以六六六，ＤＤＴ各异构体和代谢物衡量，方法的检测极限可达１．８×１０－４～８．０×１０－３μｇ／ｇ；方法回收率总均值分别在９１．４３％±１．７％，和９０．８８％±２．８４％；检测变异系数为０．２７％～９．９３％。样品测定结果显示，庆余肾气丸、复方丹参片中有机氯农药残留量皆低于世界各国的限量标准。     

一种有效提高小丸微波干燥能力及质量的装置

介绍一种能提高小丸微波干燥能力,避免小丸干燥开裂、过火等现象,可以提高小丸微波干燥均匀度的装置。     

黄芪丹参复方成分对一氧化氮合成阻滞孕鼠模型血浆IL-1、IL-10变化的影响

目的探讨黄芪丹参复方成分提高胎盘血供的分子机制，为临床有效防治胎盘血供不足所致妊娠并发症提供思路。方法提取分离黄芪、丹参复方成分，运用NOS（一氧化氮合酶）阻滞剂L－精氨酸甲酯（L—NAME）建立一氧化氮合成阻滞大鼠模型，ELISA法检测妊娠18d大鼠血浆IL－1、IL－10水平。以及胎盘超微形态学变化，大鼠血压、尿蛋白变化，以及仔鼠重、肝重、脑重、胎盘重等。结果一氧化氮合成阻滞模型组IL－1含量明显高于空白组（P〈0．01），经黄芪丹参注射液治疗后，血浆IL－1水平比模型组降低（P〈0．05）；模型组IL－10含量较空白组低（P〈0．01），中药组血浆IL－10水平高于模型组（P〈0．05）；胎盘形态学、血压、尿蛋白以及仔重、仔肝重、脑重等均有显著差异（P〈0．05，P〈0．01）。结论黄芪丹参复方成分可能对妊娠早期母－胎界面免疫平衡具有调控作用，通过促进局部生理抑制性免疫反应增强和杀伤、排斥免疫反应减弱，从而有利于母胎循环构建，维持胎盘血液供应。